Absorption pharmacokinetics and feasibility of intranasal dexmedetomidine in patients under general anaesthesia.

IF 1.9 4区 医学 Q2 ANESTHESIOLOGY Acta Anaesthesiologica Scandinavica Pub Date : 2024-06-19 DOI:10.1111/aas.14473
Suvi-Maria Tiainen, Brian J Anderson, Ella Rinne, Aleksi Tornio, Marica T Engström, Teijo I Saari, Panu Uusalo
{"title":"Absorption pharmacokinetics and feasibility of intranasal dexmedetomidine in patients under general anaesthesia.","authors":"Suvi-Maria Tiainen, Brian J Anderson, Ella Rinne, Aleksi Tornio, Marica T Engström, Teijo I Saari, Panu Uusalo","doi":"10.1111/aas.14473","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The use of intranasal dexmedetomidine is hampered by a limited understanding of its absorption pharmacokinetics.</p><p><strong>Methods: </strong>We examined the pharmacokinetics and feasibility of intranasal dexmedetomidine administered in the supine position to adult patients undergoing general anaesthesia. Twenty-eight patients between 35 and 80 years of age, ASA 1-3 and weight between 50 and 100 kg, who underwent elective unilateral total hip or knee arthroplasty under general anaesthesia were recruited. All patients received 100 μg of intranasal dexmedetomidine after anaesthesia induction. Six venous blood samples (at 0, 5, 15, 45, 60, 240 min timepoints from dexmedetomidine administration) were collected from each patient and dexmedetomidine plasma concentrations were measured. Concentration-time profiles after nasal administration were pooled with earlier data from a population analysis of intravenous dexmedetomidine (n = 202) in order to estimate absorption parameters using nonlinear mixed effects. Peak concentration (C<sub>MAX</sub>) and time (T<sub>MAX</sub>) were estimated using simulation (n = 1000) with parameter estimates and their associated variability.</p><p><strong>Results: </strong>There were 28 adult patients with a mean (SD) age of 66 (8) years and weight of 83 (10) kg. The mean weight-adjusted dose of dexmedetomidine was 1.22 (0.15) μg kg<sup>-1</sup>. C<sub>MAX</sub> 0.273 μg L<sup>-1</sup> was achieved at 98 min after intranasal administration (T<sub>MAX</sub>). The relative bioavailability of dexmedetomidine was 80% (95% CI 75-91%). The absorption half-time (T<sub>ABS</sub> = 120 min; 95% CI 90-147 min) was slower than that in previous pharmacokinetic studies on adult patients. Perioperative haemodynamics of all patients remained stable.</p><p><strong>Conclusions: </strong>Administration of intranasal dexmedetomidine in the supine position during general anaesthesia is feasible with good bioavailability. This administration method has slower absorption when compared to awake patients in upright position, with consequent concentrations attained after T<sub>MAX</sub> for several hours.</p>","PeriodicalId":6909,"journal":{"name":"Acta Anaesthesiologica Scandinavica","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Anaesthesiologica Scandinavica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/aas.14473","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The use of intranasal dexmedetomidine is hampered by a limited understanding of its absorption pharmacokinetics.

Methods: We examined the pharmacokinetics and feasibility of intranasal dexmedetomidine administered in the supine position to adult patients undergoing general anaesthesia. Twenty-eight patients between 35 and 80 years of age, ASA 1-3 and weight between 50 and 100 kg, who underwent elective unilateral total hip or knee arthroplasty under general anaesthesia were recruited. All patients received 100 μg of intranasal dexmedetomidine after anaesthesia induction. Six venous blood samples (at 0, 5, 15, 45, 60, 240 min timepoints from dexmedetomidine administration) were collected from each patient and dexmedetomidine plasma concentrations were measured. Concentration-time profiles after nasal administration were pooled with earlier data from a population analysis of intravenous dexmedetomidine (n = 202) in order to estimate absorption parameters using nonlinear mixed effects. Peak concentration (CMAX) and time (TMAX) were estimated using simulation (n = 1000) with parameter estimates and their associated variability.

Results: There were 28 adult patients with a mean (SD) age of 66 (8) years and weight of 83 (10) kg. The mean weight-adjusted dose of dexmedetomidine was 1.22 (0.15) μg kg-1. CMAX 0.273 μg L-1 was achieved at 98 min after intranasal administration (TMAX). The relative bioavailability of dexmedetomidine was 80% (95% CI 75-91%). The absorption half-time (TABS = 120 min; 95% CI 90-147 min) was slower than that in previous pharmacokinetic studies on adult patients. Perioperative haemodynamics of all patients remained stable.

Conclusions: Administration of intranasal dexmedetomidine in the supine position during general anaesthesia is feasible with good bioavailability. This administration method has slower absorption when compared to awake patients in upright position, with consequent concentrations attained after TMAX for several hours.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
全身麻醉患者鼻内右美托咪定的吸收药代动力学和可行性。
背景:由于对右美托咪定的吸收药代动力学了解有限,鼻内使用右美托咪定受到阻碍:由于对右美托咪定的吸收药代动力学了解有限,鼻内注射右美托咪定的使用受到了阻碍:我们研究了对接受全身麻醉的成年患者仰卧位鼻内注射右美托咪定的药代动力学和可行性。我们招募了 28 名年龄在 35 岁至 80 岁之间、ASA 1-3 级、体重在 50 公斤至 100 公斤之间、在全身麻醉下接受择期单侧全髋关节或膝关节置换术的患者。所有患者在麻醉诱导后都接受了 100 μg 右美托咪定的鼻内注射。从每位患者身上采集了六份静脉血样本(分别在给药后 0、5、15、45、60 和 240 分钟的时间点),并测量了右美托咪定的血浆浓度。鼻腔给药后的浓度-时间曲线与之前静脉注射右美托咪定的群体分析数据(n = 202)进行了汇总,以便使用非线性混合效应估算吸收参数。通过模拟(n = 1000)估计了峰值浓度(CMAX)和时间(TMAX),并得出了参数估计值及其相关变异性:共有 28 名成年患者,平均(标清)年龄为 66(8)岁,体重为 83(10)公斤。体重调整后的右美托咪定平均剂量为 1.22 (0.15) μg kg-1。鼻内给药后 98 分钟达到 CMAX 0.273 μg L-1(TMAX)。右美托咪定的相对生物利用度为 80%(95% CI 75-91%)。吸收半衰期(TABS = 120 分钟;95% CI 90-147 分钟)比以往对成年患者进行的药代动力学研究要慢。所有患者的围手术期血流动力学均保持稳定:结论:全身麻醉期间仰卧位鼻内注射右美托咪定是可行的,生物利用度良好。这种给药方法与直立体位的清醒患者相比,吸收速度较慢,因此在TMAX后数小时才能达到浓度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.30
自引率
9.50%
发文量
157
审稿时长
3-8 weeks
期刊介绍: Acta Anaesthesiologica Scandinavica publishes papers on original work in the fields of anaesthesiology, intensive care, pain, emergency medicine, and subjects related to their basic sciences, on condition that they are contributed exclusively to this Journal. Case reports and short communications may be considered for publication if of particular interest; also letters to the Editor, especially if related to already published material. The editorial board is free to discuss the publication of reviews on current topics, the choice of which, however, is the prerogative of the board. Every effort will be made by the Editors and selected experts to expedite a critical review of manuscripts in order to ensure rapid publication of papers of a high scientific standard.
期刊最新文献
Prevalence and etiology of ventilator-associated pneumonia during the COVID-19 pandemic in Denmark: Wave-dependent lessons learned from a mixed-ICU. Lack of correlation between biomarkers and acute kidney injury after pediatric cardiac surgery with cardiopulmonary bypass: Should be look for something else? Quantity: More markers, more merit Serious adverse events reporting in recent randomised clinical trials in intensive care medicine – A methodological study protocol In-hospital cardiac arrest registries and aetiology of cardiac arrest.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1